Related Experiment Video

Updated: Jun 22, 2025

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

10.6K

Role of Thiamine Supplementation in the Treatment of Chronic Heart Failure: An Updated Meta-Analysis of Randomized

Shuai He1, Shasha Wang2, Tingli Xu2

  • 1Department of Hand and Foot Surgery, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.

Clinical Cardiology
|June 28, 2024
PubMed

Insights

Thiamine supplementation does not directly improve chronic heart failure (CHF) outcomes. However, it effectively addresses thiamine deficiency (TD) in patients with CHF.

Area of Science:

  • Cardiology
  • Nutritional Science
  • Clinical Research

Background:

  • Chronic heart failure (CHF) presents a significant global health challenge.
  • The role of thiamine supplementation in managing CHF remains unclear, necessitating further investigation.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of thiamine supplementation in patients diagnosed with chronic heart failure.
  • To determine if thiamine supplementation offers benefits beyond correcting thiamine deficiency in CHF patients.

Main Methods:

  • A systematic literature search was performed across major databases (Cochrane Library, PubMed, EMBASE, ClinicalTrials.gov, Web of Science) up to May 2023.
  • Seven randomized controlled trials (RCTs), including parallel and crossover designs with 274 participants, were included in the meta-analysis.

Main Results:

  • Thiamine supplementation showed no significant improvement in left ventricular ejection fraction, left ventricular end-diastolic volume, 6-minute walking test, NT-proBNP levels, or NYHA class compared to placebo.
  • Thiamine supplementation was effective in improving the status of thiamine deficiency (TD).

Conclusions:

  • Thiamine supplementation does not appear to have a direct therapeutic effect on the cardiac function or clinical status of patients with CHF.
  • The primary benefit of thiamine supplementation in this population is the correction of thiamine deficiency.
Abstract

Keywords:
cardiac functionchronic heart failurethiaminethiamine deficiency

More Related Videos

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

6.9K
Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.3K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419